Struck me a night or two ago. I immediately thought that it was VERY odd that enrollment simply... stopped. Doesn't make sense to me, even with the remdesivir EUA. Remdesivir hasn't been available for most patients, so I would still expect interest in trial enrollment.

Hey, I'm probably wrong. But it's odd. And I'm having a hard time fully dispelling the notion. Speaking of December 17th, that was a similarly vague PR. "Comprehensive update about the company" or something like that.

Guess we'll find out in about two hours.